Stay updated on Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The revision label in the footer changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.
    Difference
    0.3%
    Check dated 2026-11-01T01:38:19.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A banner announces an NIH content transition, saying that some NIH materials may use “Super Intelligence” in place of “Artificial Intelligence” under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-25T01:35:39.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T01:17:05.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T01:51:06.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study page now loads as a 403 Forbidden error, replacing the expected study record with an access-restricted page.
    Difference
    19%
    Check dated 2026-09-20T00:32:25.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6 on the page, indicating a new build of the site hosting the record. This update does not modify study details, eligibility criteria, or results and likely reflects a minor backend/UI improvement.
    Difference
    0.1%
    Check dated 2026-08-29T20:40:36.000Z thumbnail image

Stay in the know with updates to Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab/Olaparib Combo in Triple-Negative Breast Cancer Clinical Trial page.